Catequentinib

Catequentinib (INN; formerly anlotinib) is a pharmaceutical drug for the treatment of cancer. It is approved in China for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have undergone progression or recurrence after at least two lines of systemic chemotherapy.^[1] It is also approved in China as a second‑line treatment for advanced soft-tissue sarcoma.^[2]

Catequentinib

Clinical data
Trade names	Focus V
Other names	Anlotinib; AL3818; AL-3818
Identifiers
IUPAC name 1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine
CAS Number	1058156-90-3
PubChem CID	25017411
IUPHAR/BPS	9601
DrugBank	DB11885
ChemSpider	45743493
UNII	GKF8S4C432
KEGG	D12526
ChEMBL	ChEMBL4303201
Chemical and physical data
Formula	C23H22FN3O3
Molar mass	407.445 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
InChI InChI=InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3 Key:KSMZEXLVHXZPEF-UHFFFAOYSA-N

Catequentinib is a tyrosine kinase inhibitor that targets several different proteins including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.^[3]

Adverse effects include hypertension, fatigue, thyroid-stimulating hormone elevation, and hand-foot syndrome, among others.^[4]